B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think
B-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an alternative to rituximab in the management of diff...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2026-03-01
|
| Edice: | Kidney Medicine |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2590059526000294 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|